Ser1290
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1290  -  LRRC16 (human)

Site Information
DDIPDsPssPKVALL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3202050

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
breast cancer ( 2 , 3 ) , lung cancer ( 1 , 3 ) , non-small cell lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
BT-20 (breast cell) ( 3 ) , H2009 (pulmonary) ( 3 ) , H2887 (pulmonary) ( 3 ) , H322 (pulmonary) ( 3 ) , HCC1359 (pulmonary) ( 3 ) , HCC1937 (breast cell) ( 3 ) , HCC4006 (pulmonary) ( 3 ) , HCC827 (pulmonary) ( 3 ) , HOP62 (pulmonary) ( 3 ) , LCLC-103H (pulmonary) ( 3 ) , lung ( 1 ) , MCF-7 (breast cell) ( 3 ) , MDA-MB-468 (breast cell) ( 3 ) , NCI-H1395 (pulmonary) ( 3 ) , NCI-H157 (pulmonary) ( 3 ) , NCI-H1666 (pulmonary) ( 3 ) , NCI-H2030 (pulmonary) ( 3 ) , SKBr3 (breast cell) ( 2 )

Upstream Regulation
Treatments:
lapatinib ( 2 )

References 

1

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

2

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

3

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info